ReviewWorld journal of diabetes2019
Crosstalk between gut microbiota and antidiabetic drug action.
Review in World journal of diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.Frontiers in endocrinology · 2020Pooled it
- Efficacy of probiotic co-supplementation with omega-3 PUFAs on pancreatic beta-cell function in type 2 diabetes.Scientific reports · 2025Trial
- Probiotic co-supplementation with absorbent smectite for pancreatic beta-cell function in type 2 diabetes: a secondary-data analysis of a randomized double-blind controlled trials.Frontiers in endocrinology · 2024Trial
- Increased circulating butyrate and ursodeoxycholate during probiotic intervention in humans with type 2 diabetes.BMC microbiology · 2022Trial
- Effects of vancomycin-induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects.Clinical and translational science · 2021Trial
- Interactions Between the Gut Microbiome and Genetic and Clinical Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus from Different Geographical Regions of Argentina.Life (Basel, Switzerland) · 2026Article
- The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study.Therapeutic advances in musculoskeletal disease · 2026Article
- Exploring the gut microbiome in type 2 diabetes across different insulin resistance levels: a machine learning approach.Frontiers in nutrition · 2026Article
- A case series of vildagliptin-associated bullous pemphigoid - Rare side effect.Indian journal of pharmacology · 2025Article
- SGLT-2 Inhibitors and Metabolic Outcomes: A Primary Data Study Exploring the Microbiota-Diabetes Connection.Metabolites · 2025Article
- The role of gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy.Frontiers in immunology · 2025Review
- Article
- Decoding the Gut Microbiota-Gestational Diabetes Link: Insights from the Last Seven Years.Microorganisms · 2024Review
- The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Unveiling the Therapeutic Potential of Berberine in Rheumatoid Arthritis: A Comprehensive Study of Network Pharmacology, Metabolomics, and Intestinal Flora.Journal of inflammation research · 2024Article
- Gut microbiota and therapy for obesity and type 2 diabetes.Frontiers in endocrinology · 2024Review
- Hybridization alters red deer gut microbiome and metabolites.Frontiers in microbiology · 2024Article
- Advances in the mechanism of metformin with wide-ranging effects on regulation of the intestinal microbiota.Frontiers in microbiology · 2024Review
- Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Comparison of the Activity of Fecal Enzymes and Concentration of SCFA in Healthy and Overweight Children.Nutrients · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes (T2D) is a disorder characterized by chronic inflated blood glucose levels (hyperglycemia), at first due to insulin resistance and unregulated insulin secretion but with tendency towards global spreading. The gut microbiota is recognized to have an influence on T2D, although surveys have not formed a clear overview to date. Because of the interactions between gut microbiota and host homeostasis, intestinal bacteria are believed to play a large role in various diseases, including metabolic syndrome, obesity and associated disease. In this review, we highlight the animal and human studies which have elucidated the roles of metformin, α-glucosidase inhibitors, glucagon-like peptide-1 agonists, peroxisome proliferator-activated receptors γ agonists, inhibitors of dipeptidyl peptidase-4, sodium/glucose cotransporter inhibitors, and other less studied medications on gut microbiota. This review is dedicated to one of the most widespread diseases, T2D, and the currently used antidiabetic drugs and most promising new findings. In general, the gut microbiota has been shown to have an influence on host metabolism, food consumption, satiety, glucose homoeostasis, and weight gain. Altered intestinal microbiota composition has been noticed in cardiovascular diseases, colon cancer, rheumatoid arthritis, T2D, and obesity. Therefore, the main effect of antidiabetic drugs is on the microbiome composition, basically increasing the short-chain fatty acids-producing bacteria, responsible for losing weight and suppressing inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.